Background
Phase III RCT (ESPAC-4). 732 patients with resected pancreatic ductal adenocarcinoma at 92 hospitals in Europe. Randomized 1:1 to gemcitabine + capecitabine versus gemcitabine alone for 6 months.
Interventions and follow up
Arm A: Gemcitabine 1,000 mg/m² days 1, 8, 15 every 4 weeks ×6 cycles + capecitabine 1,660 mg/m²/day days 1–21 every 4 weeks ×6 cycles
Arm B: Gemcitabine 1,000 mg/m² days 1, 8, 15 every 4 weeks ×6 cycles
Primary endpoint: Overall survival
Median follow-up: 43.2 months
Arm B: Gemcitabine 1,000 mg/m² days 1, 8, 15 every 4 weeks ×6 cycles
Primary endpoint: Overall survival
Median follow-up: 43.2 months
Results
mOS: 28.0 months (gem+cap) vs 25.5 months (gem alone), HR 0.82, 95% CI 0.68–0.98, P=.032
5-yr OS: 28.8% vs 16.3%
5-yr OS: 28.8% vs 16.3%
Adverse events
Overall: Grade ≥3 AEs 63% vs 55%; treatment completion 58% vs 64%.
Gastrointestinal/skin: Grade ≥3 diarrhea 5% vs 2%; grade ≥3 hand-foot syndrome 7% vs 1%.
Hematologic: Grade ≥3 hematologic toxicity comparable between arms.
Gastrointestinal/skin: Grade ≥3 diarrhea 5% vs 2%; grade ≥3 hand-foot syndrome 7% vs 1%.
Hematologic: Grade ≥3 hematologic toxicity comparable between arms.
Conclusions
Gemcitabine + capecitabine significantly improved OS versus gemcitabine alone (HR 0.82, P=.032), with a 12.5% 5-year OS benefit (28.8% vs 16.3%). This combination became a standard adjuvant option for patients who cannot receive mFOLFIRINOX.
Key Limitations
Only modest absolute median OS benefit (~2.5 months). Compliance was lower in the combination arm. Not compared directly with mFOLFIRINOX (PRODIGE-24 established mFOLFIRINOX superiority over gemcitabine alone, with no head-to-head versus gem+cap). Patients with PS ≥2 or significant comorbidities may not tolerate the combination. Both R0 and R1 resections were included, with differing subgroup OS results.
Clinical Context
ESPAC-4 established gemcitabine + capecitabine as a preferred adjuvant regimen for patients ineligible for mFOLFIRINOX. PRODIGE-24 (2018) subsequently showed mFOLFIRINOX superior to gemcitabine alone (HR 0.64). ESMO guidance recommends mFOLFIRINOX for fit (PS 0-1) patients tolerating adjuvant intensification, and gemcitabine + capecitabine for those with PS 1-2 or unable to tolerate oxaliplatin/irinotecan.
References
References: Neoptolemos JP et al, Lancet 2017 (ESPAC-4)